Pulmonary Rehabilitation for Long COVID (Post COVID-19 Condition)
- Conditions
- Long COVIDCOVID-19Post COVID-19 Condition
- Interventions
- Other: Pulmonary rehabilitation in primary care
- Registration Number
- NCT05244044
- Lead Sponsor
- University Hospital, Antwerp
- Brief Summary
In the PuRe COVID study (a randomized, controlled, multicenter, pragmatic trial) the investigators aim to assess the effect of a pulmonary rehabilitation program in primary care on exercise capacity (6MWT) and daily life physical activity in patients with long COVID.
134 patients with long COVID, defined by self-reported persistent COVID related symptoms ≥6 weeks after COVID-19 infection and a positive symptom score (CAT score ≥10 or mMRC score ≥2 or CIS-fatigue ≥36 or PCFS score of ≥2), will be recruited and divided into an intervention group or a control group. The intervention group will get twelve weeks of primary care pulmonary rehabilitation (PR) including coaching by primary care physiotherapists. The control group consists of usual care, which does not include a pulmonary rehabilitation program.
This study will help determine whether the type of symptoms or affected body system can impact recovery form long covid during rehabilitation and after follow-up. The investigators will analyze determinants and risk factors that characterize non-responders and non-adherers to better understand which patients with long COVID benefit from rehabilitation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
-
Adult patients with status post COVID-19 (positive COVID-19 PCR or an official pharmacy performed antigen test or a self-performed test confirmed by a physician during the acute COVID-19 ≥ 6 weeks ago or positive antibodies before vaccination or positive antibodies before vaccination).
-
Persistent COVID related symptoms that were not present pre-COVID-19 or were less severe pre-COVID.
-
Symptomatic: quantified by dyspnea on exertion, loss of energy, fatigue or sleep impairment based upon the score of four questionnaires:
- COPD Assessment Test (CAT) ≥10, and/or
- modified Medical Research Council dyspnea scale (mMRC) ≥2, and/or
- CIS-fatigue ≥36, and/or
- post-COVID-19 Functional Status (PCFS) ≥2.
-
Patients with known or self-reported cognitive, hearing, visual, neurological or musculoskeletal conditions that make it impossible to participate in pulmonary rehabilitation.
-
Prior physiotherapy for long COVID if:
- patients who have completed ≥9 sessions of physiotherapy in total for long COVID.
- patients who completed any physiotherapy session in the previous 12 weeks for long COVID (primary care or hospital based; pulmonary or non-pulmonary).
-
Patients with predominantly neurological disorders impacting respiratory function will not be eligible for the study.
-
Patients that are not able to give informed consent or not able to complete questionnaires.
-
Patients who have had any organ transplatation in the past, have to undergo any transplantation or are on an active transplantation list.
-
Patients with active malignancy and/or (maintenance) treatment for active malignancy or curatively treated carcinoma within the past year.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pulmonary rehabilitation group Pulmonary rehabilitation in primary care The intervention group receives a 12 weeks pulmonary rehabilitation program supervised by a primary care physiotherapist consisting of maximum 36 sessions (3 sessions per week).
- Primary Outcome Measures
Name Time Method Exercise capacity Baseline - 12 weeks Change in functional exercise capacity measured by 6-minute walk test (6MWT).
- Secondary Outcome Measures
Name Time Method Change in physical activity Baseline - 12 weeks Change in physical activity as objectively measured by an activity tracker (number of steps).
Change in COVID-19 related symptoms Baseline - 12 weeks - 24 weeks - 36 weeks The COVID-19 related symptoms will be measured with the COPD assessment test (CAT). The total CAT score ranges from 0 to 40 where 0 represents no symptoms and 40 very bad symptoms.
Change in quality of life Baseline - 12 weeks - 24 weeks - 36 weeks The quality of life will be measured with the EQ-5D-5L.
Change in dyspnoea Baseline - 24 weeks - 36 weeks Changes in dyspnoea, measured with the modified medical research council (mMRC). The total mMRC scale ranges from 0 to 4 score where 0 represents no dyspnoea and 4 a lot of dyspnoea.
Change in functional status Baseline - 12 weeks - 24 weeks - 36 weeks The functional status will be measured by the post COVID-19 functional status scale (PCFS). It is an ordinal score ranging from 0 to 4 where 4 means the patient has a lot of limitations in daily life.
Change in exercise capacity Baseline - 24 weeks The functional exercise capacity will be measured by 6-minute walk test (6MWT).
Predictors of response in 6- minute walk distance (6MWD) Post pulmonary rehabilitation The predictors will be based on baseline symptom scores (CAT, mMRC, CIS), baseline 6MWD and hospitalisation status.
Change in fatigue Baseline - 12 weeks - 24 weeks - 36 weeks The changes of the level of fatigue will be measured with the Checklist Individual Strength -fatigue (CIS-fatigue) score. The total CIS-fatigue score ranges from 20 to 140 where 20 represents no symptoms and 140 very bad symptoms.
Change in work productivity and activity impairment. Baseline - 24 weeks - 36 weeks This will be measured with the "work productivity and activity impairment" questionnaire (WPAI), consisting of 6 questions.
Change in anxiety and depression symptoms. Baseline - 24 weeks - 36 weeks This will be measured by the Hospital Anxiety and depression scale (HADS). The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.
Change in dysfunctional breathing Baseline - 24 weeks - 36 weeks This will be measured with the Nijmegen questionnaire. 16 questions will be asked, ranging from 0 to 4. The higher the score, the more likely it is that they have dysfunctional breathing.
Trial Locations
- Locations (2)
UHAntwerp
🇧🇪Edegem, Antwerp, Belgium
Ziekenhuis Oost-Limburg
🇧🇪Genk, Limburg, Belgium